# Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors

> **NCT00005061** · PHASE1 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 20 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00005061
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2001-06
- **Final completion:** —
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2012-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005061, "Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*